Preface – ASCO 2016
Preface – ASCO 2016 Paul A. Bunn Jr., MD, FA
Enhancing the profile of KRAS-mutant lung cancer
Enhancing the profile of KRAS-mutant lung cancer
Anti-angiogenic and immunotherapeutic approaches in mesothelioma
Anti-angiogenic and immunotherapeutic approaches
Interview: Lung cancer in China: hurdles and progress
Lung cancer in China: hurdles and progress Yi
Real-world utility of ctDNA NGS to identify matched targeted therapy
Real-world utility of ctDNA NGS to identify matc
Further defining the optimal use of immune checkpoint inhibitors
Further defining the optimal use of immune check
Established targeted agents taking root in the HER2-positive setting
Established targeted agents taking root in the H
Diagnostics of EGFR-mutant disease: biomarkers with significant clinical implications
Diagnostics of EGFR-mutant disease: biomarkers w
Reducing the danger that arises from the CNS as a site of progression
Reducing the danger that arises from the CNS as
New standards of care for ALK-positive disease
New standards of care for ALK-positive disease
